Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04469517 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 6, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jun 30, 2024 to Dec 31, 2025
    • Study completion date: Oct 1, 2024 to Oct 1, 2026
    v6
  2. Primary completion date: Jun 30, 2022 to Jun 30, 2024
    • Study completion date: Oct 1, 2022 to Oct 1, 2024
    v5
  3. Primary completion date: Dec 31, 2021 to Jun 30, 2022
    • Study completion date: Jun 1, 2022 to Oct 1, 2022
    v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 1, 2020 to Aug 10, 2020
    v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with hereditary hemorrhagic telangiectasia (HHT) suffer from an inherited disorder leading to systemic vascular malformations. Mutations in several genes of the transforming growth factor (TGF)-β superfamily pathway influence angiogenesis in patients with HHT. The genetic loss of ALK1 or ENG alone are not sufficient to induce AVMs; environmental insults that could trigger angiogenesis (e.g. wounding) are also needed. In this study it will be analyzed if hypoxic induced factors could have an influence on the disease HHT.
Trial Details
NCT Number NCT04469517
Lead Sponsor University Hospital, Essen
Conditions
(from sponsor)		 Hereditary Hemorrhagic Telangiectasia
Related terms Telangiectasia, Hereditary Hemorrhagic
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov